anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The existence of unconscious visually triggered behavior in patients with cortical blindness (e.g., homonymous hemianopia) has been amply demonstrated and the neural bases of this phenomenon have been thoroughly studied. However, a crosstalk between the two hemispheres as a possible mechanism of unconscious or partially conscious vision has not been so far considered. Thus, the aim of this study was to assess the relationship between structural and functional properties of the corpus callosum (CC), as shown by probabilistic tractography (PT), behavioral detection/discrimination performance and level of perceptual awareness in the blind field of patients with hemianopia. Twelve patients were tested in two tasks with black-and-white visual square-wave gratings, one task of movement and the other of orientation. The stimuli were lateralized to one hemifield either intact or blind. A PT analysis was carried out on MRI data to extract fiber properties along the CC (genu, body, and splenium). Compared with a control group of participants without brain damage, patients showed lower FA values in all three CC sections studied. For the intact hemifield we found a significant correlation between PT values and visual detection/discrimination accuracy. For the blind hemifield the level of perceptual awareness correlated with PT values for all three CC sections in the movement task. Importantly, significant differences in all three CC sections were found also between patients with above-vs. chance detection/discrimination performance while differences in the genu were found between patients with and without perceptual awareness. Overall, our study provides evidence that the properties of CC fibers are related to the presence of unconscious stimulus detection/discrimination and to hints of perceptual awareness for stimulus presentation to the blind hemifield. These results underline the importance of information exchange between the damaged and the healthy hemisphere for possible partial or full recovery from hemianopia.
The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
A system (SYS) and associated method for imaging support. The system (SYS) comprises a Stimulus Delivery Component (SDC), a Response Measurement Component (RMC) and a decision logic unit (DL). The stimulation delivery component is configured to cause chemoreceptor stimulation in a patient residing in or at an imaging device (IA). The response measurement component measures a response of the patient to the stimulus. The decision logic unit (DL) establishes a sedation state of the patient based on the measured response for the purpose of imaging the patient. If the patient is no longer sedated sufficiently, the imaging procedure can be modified, for example.
The present invention is related to a core-shell photo-chemo nanomedicine aiding sequential or simultaneous delivery of a photosensitizer drug and at least one chemotherapeutic drug for combinatorial photodynamic therapy and chemotherapy of cancer. The nanomedicine core is made up of a biodegradable or biocompatible polymer and the shell is either by polymer or a protein aiding the following two configurations; (i) polymer core-polymer shell and (ii) polymer core-protein shell. The core-shell nanomedicine is made in such a way that, while the core is loaded with photosensitizer, the shell will be loaded with a chemo-drug or vice-versa. Along with improving drug solubility, stability, bioavailability and therapeutic efficiency, the core-shell nanomedicine platform aids sequential or simultaneous delivery of photosensitizer and chemo drugs to cancer type diseases and thereby facilitates the application of photodynamic reactive oxygen stress together with or followed by chemotherapy. In addition, this core-shell nanomedicine can be targeted specifically to the disease site by conjugating with targeting molecules such as antibodies, peptides, small molecules, vitamins, proteins, etc. This core-shell photo-chemo nanomedicine system is capable of excreting photodynamic reactive oxygen stress together with or followed by chemotherapy.
Peak oxygen consumption was measured by gas-analysis. Myocardial function was measured by echocardiography. Exercise was performed on treadmills under close supervision of an exercise physiologist. Patients had to complete over 70% of sessions to be included in analysis. Three sessions were scheduled every week. Heart rate (HR) was about 85 % of max HR in the high intensity group, and about 65 % in the moderate intensity group.
This is an open-label, single-dose, single-period, non-randomised study in healthy male subjects. Subjects will be screened for eligibility to participate in the study between 28 and 2 days before dosing. Eligible subjects will be admitted to the clinical unit on the evening of the day before dosing (Day -1). Subjects will be dosed on the morning of Day 1 following an overnight fast of approximately 8 h. Blood, urine, faeces and expired air will be collected at predefined time points for mass balance and PK analysis. Subjects will remain resident in the clinic until the morning of Day 22, when they will be discharged as a group.

Single dose administration on a single occasion. The estimated duration of the study from screening until the final return visit is approximately 3.5 months.
Alcohol use is the most common underlying cause of injuries in the United States. There is a growing body of literature suggesting that brief interventions (BI), in the form of a short (10-60 minute) counseling session, may decrease alcohol consumption and its harmful consequences. In contrast to the abundant literature on the effectiveness of BI in the outpatient setting, only 3 randomized controlled trials have been performed an adults specifically in the setting of acute trauma, and have had inconclusive results. All three studies used highly trained persons to perform the BI, and all were greater than 30 minutes in duration, a situation that may not necessarily reflect the practicalities of routine medical care. This raises the question of whether the benefits seen in these studies reflect the expertise of a small number of individuals or whether the effects correlate with the amount of time spent with the patient. Highly trained personnel and time are valuable commodities in a busy trauma center and may not be feasible given the competing clinical demands. We propose to investigate whether BI are effective in a setting that is more likely to reflect "real world" of clinical medicine rather than an idealized setting, utilizing trauma nurse practitioners to perform brief (5-10 minute) interviews.

We will identify all patients admitted with trauma who test positive on a blood alcohol test. These patients will be consented and randomized to either a brief intervention group, or a standard medical care group. All patients will receive an AUDIT questionnaire to identify patterns of drinking behavior and an alcohol information pamphlet. After discharge, patients will be telephoned at 1,6, and 12 months. The first 2 contacts will be to see how the patient is doing and to verify the contact information. The AUDIT questionnaire will be re-administered during the 12 month interview.
It has generally been accepted that vitamin E refers to a group of tocochromanols, α-, β-, γ-, and δ-tocopherols and the corresponding four tocotrienols. Recently, Azzi and colleagues proposed to restrict the term vitamin E only to RRR-α-tocopherol, not to other tocopherols and tocotrienols (Azzi A et al. Free Radic Biol Med. 2023; 207:178-180. doi: 10.1016/j.freeradbiomed.2023.06.029). The aim of this paper is to express our opinion on the nomenclature of vitamin E based on available scientific data. In our opinion, it would be inappropriate to exclude all the tocochromanols other than RRR-α-tocopherol from the vitamin E group at this stage when the molecular mechanisms showing how vitamin E deficiency causes diseases such as ataxia and how vitamin E prevents/reverses such diseases are not elucidated. Understanding of whole functions of tocochromanols including underlying mechanisms and dynamics is essential before revision of currently accepted definition of vitamin E. The potential roles of γ-tocopherol and tocotrienols are discussed despite whether they are vitamin function should be clarified in the future studies.
PROBLEM TO BE SOLVED: To obtain the subject composition which can reduce time for drying without using a specific additive or the like by including nitrocellulose, cellulose ester and dye in a specific ratio. SOLUTION: This manicure composition is obtained by including, in a solvent medium (e.g. methyl ethyl ketone), (A) a cellulose ester, preferably cellulose acetate, acetopropionate, acetobutyrate or the like, (B) nitrocellulose, and, as required, (C) an additional film-forming polymer (e.g. polyvinyl butyral) at below 50 wt.% based on the total weight of the components A and B, and (D) a dye (e.g. titanium dioxide and manganese violet). It is preferable that cellulose acetobutyrate or acetopropionate as the component A is included at 10 to 80 wt.%, and the component B at 1.5 to 35 wt.%, both based on the total weight of the components A and B. It is also preferable that the component D is included at 0.001 to 10 wt.%, based on the whole composition.
Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
A process of tissue regeneration is provided that includes the administration of a stem cell topically to a surface of a tissue. The tissue being in vivo in a subject or in vitro. The tissue has a biocompatible matrix applied around the stem cell and in contact with the surface. After sufficient time, the stem cell infiltrates and regenerates the tissue. A composition is also provided that includes an injured or diseased tissue with a plurality of stem cells proximal to the tissue surface in a biocompatible. A process of increasing a level of cytokines, chemokines, growth factors, anti-apoptotic or anti-necrotic factors in a tissue is provided that includes the administration of a stem cell topically to a surface of a tissue in a biocompatible matrix. After sufficient time, the stem cell releases soluble pro-regenerative factors to increase the levels in the tissue.
Invention herewith described refers to the daily cream against acnes for young people. The aim is to prevent the occurrence of acnes and the rapid elimination of their consequences. The cream against acnes is made on a fully natural basis from the highest quality natural oils and extracts, without preservatives and other harmful ingredients such as mercury. After use, there is noticeable the complete disappearance of acnes, and the preventive use reduces the chances for their occurrence. The cream against acnes for the prevention of their occurrence and elimination of the consequences is made of 80 grams of Vaseline that is melted with 30 gr of Lanoline at 100 degrees Celsius. After that, the mixture is left to cool for 20 minutes, and then is stirred gradually adding distilled water (Aqua distillates) warmed to 30 degrees Celsius and 50 ml of almond oil. The cream is stirred in an appropriate container for another 15 minutes with the addition of 5 ml of AD drops. Then, the mass is stirred for 10 minutes until it becomes thick enough that it can lubricate the skin, let to cool to room temperature for about 30 minutes and left for another 30 minutes to stabilize, and after that, it can be poured into the boxes for use.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, and describes a pharmaceutical composition for neurodegenerative diseases of hydrogenated pyrido(4,3-b)indole, a method for preparing and based drug. The pharmaceutical composition consists of hydrogenated pyrido(4,3-b)indole (Rs) and a polymeric component (Rp) selected from: blood serum albumin, sodium alginate, amylopectin, hydroxyethyl starch, dextrane, gelatin, sodium caseinate, carboxymethyl cellulose, carrageenan, starch, phosphorylated starch, lactalbumin, methylcellulose, ovalbumin, pectin, polyvinylpyrrolidone, sodium polygalacturonate, lactic-co-glycolic acid, cyclodextrin, (2-hydroxypropyl)cyclodextrin or their mixtures, and Rs and Rp are associated and found in the composition in the following proportions (weight fractions): Rs 10-60, Rp 40-90. The method for preparing the declared pharmaceutical composition consists in the fact that the components Rs and Rp are dissolved in a common solvent, kept at temperature -40 to +50C for 0.5 to 8 h and dried by the known method. ^ EFFECT: group of inventions solves a problem of preparing the drugs which would exhibit high therapeutic activity in small doses and would not cause side effects. ^ 3 cl, 3 ex, 3 tbl
Protocol Summary: Optune therapy is a newly approved treatment for patients with glioblastoma. This therapy demonstrated comparable outcomes for patients with recurrent GBM, in comparison to standard therapies, but better quality of life. More recently, in an interim analysis of 315 patients with GBM, adding Tumor Treating Fields (TTFields) to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. It also has demonstrated promise in other cancers such as pancreas, mesothelioma, ovarian and lung. However, in order to optimize the treatment regimen, and potentially predict which patients are most likely to respond, reliable ways of evaluation are necessary. Advanced perfusion and diffusion MRI methods have shown utility with other treatments such as bevacizumab. Preliminary data suggests the same might be true for the evaluation of Optune therapy. The team therefore proposes to determine the utility of these methods to predict response to Optune therapy. A successful result will have wide-ranging implications not only for the optimization of Optune treatment of brain cancer but also other cancers shown to benefit from this novel therapy.

Objective: To compare standard and advanced MRI for their ability to predict response to Optune therapy. The team's approach will be to obtain both standard and advanced MRI in patients with newly diagnosed glioblastoma undergoing adjuvant chemotherapy plus Optune therapy. The ability of standard and advanced MRI to predict response will be assessed. The hypothesis is that perfusion and/or diffusion imaging metrics can be used to predict response to and elucidate mechanisms of action for Optune treatment.
Down syndrome (DS) is caused by trisomy of human chromosome 21 (Hsa21). DS is a gene dosage disorder that results in multiple phenotypes including congenital heart defects. This clinically important cardiac pathology is the result of a third copy of one or more of the approximately 230 genes on Hsa21, but the identity of the causative dosage-sensitive genes and hence mechanisms underlying this cardiac pathology remain unclear. Here, we show that hearts from human fetuses with DS and embryonic hearts from the Dp1Tyb mouse model of DS show reduced expression of mitochondrial respiration genes and cell proliferation genes. Using systematic genetic mapping, we determined that three copies of the dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1a) gene, encoding a serine/threonine protein kinase, are associated with congenital heart disease pathology. In embryos from Dp1Tyb mice, reducing Dyrk1a gene copy number from three to two reversed defects in cellular proliferation and mitochondrial respiration in cardiomyocytes and rescued heart septation defects. Increased dosage of DYRK1A protein resulted in impairment of mitochondrial function and congenital heart disease pathology in mice with DS, suggesting that DYRK1A may be a useful therapeutic target for treating this common human condition.
The present invention provides a class of biochemically-activated MRI contrast agents. The agents include a paramagnetic chelate attached via a linker arm to a relaxivity-modulating group. When the relaxivity-modulating group is removed or otherwise interacts with a targeted substance, the agents are activated by various mechanisms. The activation is detectable by an increase or decrease in the relaxivity of the metal chelate. The agents are useful in the detection of biochemical parameters in cells, tissues and subjects. Exemplary biochemical parameters are markers that are associated with disease states.
<P>PROBLEM TO BE SOLVED: To provide an antitumor agent, a hyaluronidase inhibitor or a therapeutic agent of atopic dermatitis, containing fucoidan obtained from an extract of seaweeds as an active ingredient, and utilizing the bioactivities thereof.  <P>SOLUTION: The antitumor agent, the hyaluronidase inhibitor or the therapeutic agent of the atopic dermatitis contains the fucoidan obtained from Laminaria angustata var. longissima as an active ingredient. The fucoidan is obtained by extracting the Laminaria angustata var. longissima with a diluted aqueous hydrochloric acid solution, and concretely, is one or all of four fractions obtained by extracting the Laminaria angustata var. longissima with the diluted aqueous hydrochloric acid solution, converting the extract into a cetylpyridinium chloride complex of a polysaccharide, and subjecting the cetylpyridinium chloride complex of the polysaccharide to a DEAE-sepharose column.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A.beta.'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidgonic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
All men who have sex with men (MSM) and male-to-female transgender individuals who have sex with men who present to TNC for HIV testing and are at risk for HIV will be offered enrollment in this study (see study schema). Upon enrollment, subjects will be given an Ipad-based computerized questionnaire that assesses their risk perception, demographics, risk behavior, and perception of whether they are a candidate for PrEP. Upon completion of the survey they will be randomized into 1 of 2 arms. Subjects in the intervention arm will receive the results of their risk score based on a risk calculator developed at UCSD and the Center for Disease Control and Prevention's tool for Assessing Risk for Contracting HIV (ARCH, formerly known as the HIV Incidence Risk Index for MSM, or HIRI-MSM), whereas subjects in the control arm will not receive this information. Both groups will receive standard risk reduction counseling. Subjects will be contacted by phone 2 months after enrollment to determine whether they initiated PrEP or not, to re-assess their risk perception, and to provide a link to a final online survey. If subjects have not completed the survey 4 weeks after being provided with the link, they will receive a text-message reminder.

The analysis of the data will begin 12 weeks after the last study subject is enrolled.
Since this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The investigators therefore feel it is important to review the diagnosis, clinical presentation and management of X-MAID participants. The study the investigators propose will enable to understand the presentation of X-MAID participants, establish guidelines and provide the best treatment for each participant according to his or her clinical picture